Primary source: Good clinical practices: Guidance documents - Canada.ca
The guidance document specifies new timelines for SUADR reporting, requiring notification within 7 days for serious unexpected adverse reactions that occur during clinical trials, and within 15 days for events occurring outside Canada.
Compliance with these revised reporting requirements is crucial for maintaining safety standards in clinical trials and ensuring that sponsors effectively monitor and report safety data to Health Canada and investigators.
Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.
Regulatory Intelligence Lead
Review before 2026-08-14.
Updates to Serious unexpected adverse drug reaction (SUADR) reporting requirements (Section 6), adoption of ICH E6(R3) principles, and clarification of sponsor obligations for expedited reporting of safety events occurring both inside and outside Canada.
Clinical safety and PV teams must ensure that their SUADR reporting processes are aligned with the clarified 7-day and 15-day timelines for expedited notification. Sponsors must maintain robust systems for capturing safety data from international trial sites and ensuring consistent reporting to Health Canada and investigators.
Requirement to comply with updated ICH E6 standards.
Implementation of new regulations and guidelines for clinical trials.
Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.
The updated GUI-0100 aligns with ICH E6(R3) Good Clinical Practice guidelines and specifies new reporting requirements for Serious Unexpected Adverse Drug Reactions (SUADRs). Clinical safety and pharmacovigilance teams must adhere to clarified reporting timelines of 7 days for certain events and 15 days for others, applying to safety events occurring both within and outside Canada.
What changed: The guidance document specifies new timelines for SUADR reporting, requiring notification within 7 days for serious unexpected adverse reactions that occur during clinical trials, and within 15 days for events occurring outside Canada.
Why it matters: Compliance with these revised reporting requirements is crucial for maintaining safety standards in clinical trials and ensuring that sponsors effectively monitor and report safety data to Health Canada and investigators.
Practical implication: Clinical safety and pharmacovigilance teams must ensure that their SUADR reporting processes are aligned with the new 7-day and 15-day notification timelines, and maintain robust systems for collecting safety data from international sites.
Published from the Firecrawl policy change extraction pipeline.
Implement a gap analysis for 505(b)(2) applications to identify safety data needs and adjust safety monitoring systems as necessary to accommodate new product characteristics.
MAHs and sponsors must enhance their pharmacovigilance systems to monitor microbiome-specific safety issues, comply with established safety standards, and address concerns related to antimicrobial resistance.
Stakeholders, including manufacturers and clinicians, must review and potentially revise their post-market vigilance and safety monitoring protocols in response to the FDA's proposed regulatory approaches for generative AI devices.
Developers of MBMPs must align their safety assessment protocols with the MHRA's expectations and are encouraged to engage with the MHRA early to establish appropriate regulatory strategies.
